- Gilead's Complera approved for HIV patients already on stable drug regimens
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Reports: ESI may start 'price war' over new hepatitis C drugs
- Actavis launches generic version of Opana ER
- Actavis seeks approval for generic opioid-dependence drug
FOSTER CITY, Calif. — Drug maker Gilead Sciences has recalled a single lot of an injected drug used to treat an opportunistic infection in AIDS patients due to the presence of foreign matter in some vials, the company said.
Gilead announced the voluntary recall of lot B120217A of Vistide (cidofovir), an injected drug used to treat cytomegalovirus retinitis in patients with AIDS, due to particulate matter.
The company said that it had not received any complaints related to the problem, but that patients risked experiencing serious complications if injected with the particles. The lot was distributed in the United States, Canada and Europe to retail pharmacies, hospitals and wholesalers.